{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:30:35Z","timestamp":1793039435460,"version":"4.5.0"},"reference-count":60,"publisher":"Korean Liver Cancer Association","issue":"1","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Korean Liver Cancer Association Research Award"},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2023R1A2C2004339"],"award-info":[{"award-number":["2023R1A2C2004339"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["e-jlc.org"],"crossmark-restriction":true},"short-container-title":["JLC"],"published-print":{"date-parts":[[2026,3,31]]},"abstract":"<jats:p>Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality worldwide. The recent introduction of immune checkpoint inhibitors (ICIs) has transformed the therapeutic landscape for advanced HCC. Combination regimens such as atezolizumab plus bevacizumab, durvalumab plus tremelimumab, and nivolumab plus ipilimumab have demonstrated significant survival improvements over conventional tyrosine kinase inhibitors and have become the new standard of care. However, ICIs can trigger immune-related adverse events (irAEs) through overactivation of the immune system, affecting multiple organs including the skin, gastrointestinal tract, liver, endocrine system, lungs, and heart. Patients with HCC frequently have underlying liver diseases such as chronic hepatitis or cirrhosis, placing them at higher risk of hepatic irAEs compared to that with other cancer types, which can markedly influence prognosis. The pathophysiology of irAEs is driven by a series of interconnected immune mechanisms, including excessive T-cell activation, disruption of immune tolerance, cytokine dysregulation, complement-mediated injury, and innate immune activation. Clinical decisions regarding the continuation, interruption, or discontinuation of ICIs, as well as the administration of corticosteroids or immunosuppressants, should be guided by the severity of toxicity. Organ-specific management strategies and multidisciplinary collaboration are essential, particularly for severe presentations. This review summarizes the incidence, mechanisms, and management strategies for ICI-related irAEs in advanced HCC, and provides practical insights for clinical decision-making.<\/jats:p>","DOI":"10.17998\/jlc.2025.12.21","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T23:10:44Z","timestamp":1767049844000},"page":"65-82","update-policy":"https:\/\/doi.org\/10.17998\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Immune-related adverse events in hepatocellular carcinoma: organ-specific patterns and management approaches"],"prefix":"10.17998","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9524-8844","authenticated-orcid":true,"given":"Sul Ki","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4023-6090","authenticated-orcid":true,"given":"Seonjeong","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6979-5812","authenticated-orcid":true,"given":"Hong Jae","family":"Chon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7328","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0708857"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)30207-1"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.030"},{"key":"ref5","first-page":"448","volume-title":"Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","author":"Sangro","year":"2024"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)00403-9"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.08.029"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.2668"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.10.021"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-332125"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.17998\/jlc.2023.11.21"},{"key":"ref12","first-page":"1133","volume-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","author":"Qin","year":"2023"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000001385"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.03.033"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1703481"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.11.016"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1292122"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14061580"},{"key":"ref19","first-page":"029","volume-title":"Epitope spreading and the efficacy of immune checkpoint inhibition in cancer","author":"Liu","year":"2021"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.4733"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20874-x"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1908079116"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-2795"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16091759"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100672"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2200244"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008002"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0013-y"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.14218\/jctp.2022.00017"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.06.037"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1172\/jci125413"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2016.3"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00520-7"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.08.010"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.10.003"},{"key":"ref36","first-page":"431","volume-title":"Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours","author":"Celsa","year":"2024"},{"key":"ref37","first-page":"4073","volume-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","author":"Schneider","year":"2021"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435"},{"key":"ref40","first-page":"387","volume-title":"Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology","author":"Thompson","year":"2022"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31227"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0336-3"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2020.06.016"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0160-6"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209773"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31200"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1159\/000531182"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1177\/23247096241261505"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.3390\/ijtm3030019"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001322"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16198"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0000780644.17239.03"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2022-000989"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1056\/nejmc1901677"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-021-00114-x"},{"key":"ref56","first-page":"e1088","volume-title":"Rituximab treatment and long-term outcome of patients with autoimmune encephalitis: real-world evidence from the GENERATE registry","author":"Thaler","year":"2021"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2025-335998"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018894618"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1613849"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-023-03177-6"}],"container-title":["Journal of Liver Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-jlc.org\/upload\/pdf\/jlc-2025-12-21.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-jlc.org\/journal\/view.php?doi=10.17998\/jlc.2025.12.21","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-jlc.org\/upload\/pdf\/jlc-2025-12-21.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T06:04:14Z","timestamp":1775455454000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-jlc.org\/journal\/view.php?doi=10.17998\/jlc.2025.12.21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"URL":"https:\/\/doi.org\/10.17998\/jlc.2025.12.21","relation":{},"ISSN":["2288-8128","2383-5001"],"issn-type":[{"value":"2288-8128","type":"print"},{"value":"2383-5001","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"2025-10-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-29","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-31","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}